On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...